← Product Code [CAK](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/CAK) · K982822 # FENWAL 20 MICRON PEDIATRIC TRANSFUSION FILTER MODEL 4C7701, FENWAL 20 MICRON PEDIATRIC TRANSFUSION FILTER SET MODEL 4C72 (K982822) _Baxter Healthcare Corp · CAK · Sep 30, 1998 · General Hospital · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/CAK/K982822 ## Device Facts - **Applicant:** Baxter Healthcare Corp - **Product Code:** [CAK](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/CAK.md) - **Decision Date:** Sep 30, 1998 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 880.5440 - **Device Class:** Class 2 - **Review Panel:** General Hospital - **Attributes:** Pediatric ## Indications for Use The filter is intended for the removal of microaggregates from whole blood and red blood cells. ## Device Story Fenwal 20 Micron Pediatric Transfusion Filter is a depth-type filter designed to trap microaggregates (degenerating platelets, leukocytes, fibrin strands) from stored blood. Device consists of a fiber pad supported by a screen within a housing. Modification involves changing fiber composition of the pad by eliminating two of five fiber types and increasing the percentage of the remaining three, matching the composition of the Fenwal 20 Micron High Capacity Transfusion Filter. Used in clinical settings during blood transfusion to prevent microaggregate infusion. Healthcare providers use the device to filter blood products prior to patient administration, potentially reducing transfusion-related complications. ## Clinical Evidence Bench testing only. Performance compared using packed red blood cells. Metrics included filter efficiency (% microaggregate removal), filtration integrity (% hemolysis and red blood count), and filter capacity. Results indicate the modified device meets or exceeds all functional requirements. ## Technological Characteristics Depth-type filter; fiber pad composition modified to three fiber types; supported by a screen in a housing. Pediatric-sized housing. Non-electronic, mechanical filtration device. ## Regulatory Identification An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container. ## Special Controls *Classification.* Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9. ## Predicate Devices - Fenwal® 20 Micron Pediatric Transfusion Filter - Fenwal® 20 Micron High Capactiy Transfusion Filter ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ SEP 3 0 1998 510(k) Premarket Notification Fenwal® 20 Micron Pediatric Transfusion Filter K982822 #### 510(k) SUMMARY #### Submitted by: Mary Ellen Snyder Baxter Healthcare Corporation I.V. Systems Division Rte. 120 and Wilson Road Round Lake, IL 60073 #### Date Prepared: August 10, 1998 ### Proposed Device: Modified Fenwal® 20 Micron Pediatric Transfusion Filter #### Predicate Device: Fenwal® 20 Micron Pediatric Transfusion Filter Fenwal® 20 Micron High Capactiy Transfusion Filter #### Proposed Device Description: Baxter's Fenwal® 20 Micron Pediatric Transfusion Filter is a depth-type filter which traps microaggregates composed of degenerating platelets, leukocytes, fibrin strands and other particles which form in blood after storage. The filter consists of a fiber pad supported by a screen contained in a housing. The subject of this submission is a change in the fiber composition of the filter pad. The filter pad is currently comprised of five types of fiber strands. The supplier of one of the fibers has discontinued production. We are proposing to eliminate two of the five fibers used in construction of the filter pad and increase the percentage composition of the remaining three sizes. This change will make the composition of the 20 micron pediatric filter pad identical to the composition of the pad in the Fenwal® 20 Micron High Capacity Transfusion Filter covered by K830057. s:\510k\20filsum.doc **AUG 1 0 1998** {1}------------------------------------------------ ## Statement of Intended Use: The proposed Fenwal® 20 Micron Pediatric Transfusion Filter has the same intended use as the current Fenwal® 20 Micron Pediatric Transfusion Filter. The filter is intended for the removal of microaggregates from whole blood and red blood cells. # Summary of Technological Characteristics of New Device Compared to Predicate Devices The proposed Fenwal® 20 Micron Pediatric Transfusion Filter is identical to the current Fenwal 20 Micron Pediatric Transfusion Filter except for a change in the composition of the filter pad. The materials and design of all other filter components, including the filter housing and filter screen, remain unchanged. The modified 20 micron pediatric filter pad is also identical in composition to the Fenwal® 20 Micron High Capacity Filter but is physically smaller to fit into the pediatric-sized housing. ## Discussion of Nonclinical Tests; Conclusions Drawn from Nonclinical Tests Test data has been generated comparing the performance of the proposed and current 20 micron pediatric transfusion filters using packed red blood cells. Data regarding filter efficiency (% microaggregate removal), filtration integrity (% hemolysis and red blood count) and filter capacity were collected. Performance testing indicates that the modified device meets or exceeds all functional requirements and supports its suitability for use. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 SEP 3 0 1998 Ms. Mary Ellen Synder Senior Manager, Requlatory Affairs Baxter Healthcare Corporation I.V. Systems Division Route 120 and Wilson Road Round Lake, Illinois 60073 Re : K982822 Trade Name: Fenwal® 20 Micron Pediatric Transfusion Filter Model 4C7701 Regulatory Class: II Product Code: CAK Dated: August 10, 1998 Received: August 11, 1998 Dear Ms. Snyder: We have reviewed your Section 510 (k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. ਸੇ substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, ... through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 {3}------------------------------------------------ Page 2 - Ms. Synder through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, warr Timothy A. Ulatowski Director Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ 510(k) Premarket Notification Fenwal® 20 Micron Pediatric Transfusion Filter 510(k) Number: Not Available Device Name: Fenwal® 20 Micron Pediatric Transfusion Filter Indication for Use: The Fenwal® 20 Micron Pediatric Transfusion Filter is indicated for the removal of microaggregate particles from whole blood and red blood cells. Patricia Cucenite (Division Sign-Off) Division of Dental, Infection Control, and General Hospital Devices ्द 510(k) Number K98280 AUG 1 0 1998 1 BAXTER CONFIDENTIAL 61 --- **Source:** [https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/CAK/K982822](https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/CAK/K982822) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com